Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06389123 | Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas | recruiting | Phase 1 | 40 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06598800 | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 153 | BeOne MedicinesINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | BeOne MedicinesINDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06797999 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma(ADCElerate1) | recruiting | Phase 1 / Phase 2 | 270 | Adcendo ApSINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06830031 | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402) | recruiting | Phase 1 | 18 | Shanghai Exuma Biotechnology Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Elizabeth Stover, MD, PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 154 | Debiopharm International SAINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07030712 | A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) | recruiting | Phase 1 | 67 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | recruiting | Phase 1 | 56 | CerenomeINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07087002 | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | recruiting | Phase 1 | 18 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07132541 | Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)(NBCA) | recruiting | Phase 1 | 30 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07222488 | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | recruiting | Phase 1 / Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT07247110 | A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | recruiting | Phase 1 | 250 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 11, 2026 | clinicaltrials |
| NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT07586943 | SKB118 Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 530 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07719920 | A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 99 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07746141 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations | recruiting | Phase 1 | 100 | BeOne MedicinesINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814352 | A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03104491 | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 44 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer(Morpheus-panBC) | recruiting | Phase 1 / Phase 2 | 1,132 | Hoffmann-La RocheINDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT03647358 | Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma | recruiting | Phase 1 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04471987 | Safety and Early Signs of Efficacy of IL12-L19L19.(DODEKA) | recruiting | Phase 1 | 80 | Philogen S.p.A.INDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT04864054 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC(ARYA-3) | recruiting | Phase 1 / Phase 2 | 60 | Eureka Therapeutics Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | recruiting | Phase 1 | 280 | SystImmune Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | recruiting | Phase 1 | 48 | Stanford UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07231211 | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 258 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07260708 | Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers | recruiting | Phase 1 | 42 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07308132 | A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies | recruiting | Phase 1 | 340 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 10, 2026 | clinicaltrials |
| NCT07356453 | A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 40 | FoRx Therapeutics AGINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | recruiting | Phase 1 | 103 | GenmabINDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | recruiting | Phase 1 | 110 | EpiBiologicsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07570017 | A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 42 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer(VITAL-TNBC) | recruiting | Phase 1 | 60 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 39 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04049539 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | recruiting | Phase 1 / Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05010005 | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | recruiting | Phase 1 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05139056 | Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05287945 | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 75 | Oncorena ABINDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials